Skip to content

Cognitive Behavioral Therapy for Patients With an Early Psychosis

Does Cognitive Behavioral Therapy Improve Depressive Symptoms and Self-Esteem in Patients With a First Episode Psychosis? A Randomized Controlled Study

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01511406
Enrollment
60
Registered
2012-01-18
Start date
2011-01-31
Completion date
2014-10-31
Last updated
2014-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depressive Symptoms, Psychosis, Schizophrenia, Self-esteem

Keywords

Psychosis, Schizophrenia, Cognitive behavioral therapy, Self esteem, Depression

Brief summary

The purpose of the present study is to examine whether cognitive behavior therapy will reduce depressive symptoms and increase self-esteem for patients with a first episode psychosis.

Detailed description

A growing body of evidence supports the use of Cognitive Behavioural Therapy (CBT) for the treatment of schizophrenia. The strength of evidence is especially strong for patients with persistent hallucinations and delusions. As it comes to the effect of CBT for patients with a first episode psychosis the picture is more unclear. The main reason is probably that the CBT interventions to a less extent have been adjusted to fit first episode psychosis patients. The main problems for patients with a first episode psychosis (FEP) is rarely persistent hallucinations and delusions but they struggle with social anxiety, depression, alcohol and drug abuse and low self esteem. Forthcoming studies examining the effect of CBT for patients with a first episode psychosis should aim to have a focus on these symptoms. The main aim of the present study is to examine whether CBT has any effect on depressive symptoms and self-esteem in patients with a FEP. The study will include patients with a first episode psychosis with Axis-I DSM IV diagnosis of schizophrenia, schizoaffective disorder, delusional disorder, and psychosis not otherwise specified. To be included in the study the patients should meet the criteria of an affective episode the last year or have a score on Calgary Depression of Schizophrenia Scale above four. Patients are randomly selected to either a treatment group or a control (placebo) group. The aim is to include 30 patients in each group. Patients in the treatment group will receive a manual-based CBT intervention comprising up to 26 sessions during a six months period. The control group will receive treatment as usual (TAU). The patients are assessed before the entry of the study and after 6 months (end of treatment). Moreover they will be assessed after 9 months of ending therapy. Hypothesis: In this study we hypothesize that * patients receiving CBT will have less depressive symptoms than TAU-patients at the and of treatment and at six months follow up * CBT-patients will demonstrate a better improvement in their self-esteem than TAU-patients at the end of treatment and at six months follow up. To our knowledge, no previous studies have examined outcome after CBT treatment with regards to depressive symptoms and self-esteem. Furthermore, this is the first randomized controlled study in Norway of CBT among patients with a FEP.

Interventions

BEHAVIORALcognitive behavioral therapy

Patients allocated to the treatment arm will receive up to 26 sessions of cognitive behavioral therapy

Sponsors

Stiftelsen Helse og Rehabilitering
CollaboratorOTHER
Oslo University Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Participants are eligible for the study if they are diagnosed with a psychotic disorder or bipolar disorder with psychosis according to DSM-IV (i.e. schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder or psychosis NOS * Aged between 18-65 years * Are capable of giving a written consent to participate in the study.

Exclusion criteria

* A history of head injury, neurological disorders, developmental disorders, and all episodes of psychosis being judged as substance-induced rather than a primary episode of a psychotic disorder. * Being in treatment for more than five years

Design outcomes

Primary

MeasureTime frameDescription
Calgary Depression rating Scale for Schizophrenia (CDSS)up to nine months after end of interventionMeasure depressive symptoms for patients with a psychosis

Secondary

MeasureTime frameDescription
Rosenberg Self Esteem Scaleup to nine months after end of interventionMeasure the level of self esteem among patients with a psychosis

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026